Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial

BACKGROUND:

Friedreich ataxia is a rare disease caused by GAA-trinucleotide-repeat expansions in the frataxin gene, leading to marked reduction of qualitatively normal frataxin protein. Recently, human recombinant erythropoietin was reported to increase frataxin levels in patients with Friedreich ataxia.

METHODS:

Read More: Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Family B.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News